Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer

被引：0
|
作者：
Yin, Y. [1 ]
Duan, N. [1 ]
Hua, Y. [1 ]
机构：
[1] Nanjing Med Univ, Dept Oncol, Jiangsu Prov Hosp, Affiliated Hosp 1, Nanjing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1016/j.annonc.2023.09.1535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
32P
引用
收藏
页码：S196 / S197
页数：2
相关论文
共 50 条
  • [1] Epigenetic modification induced reprogramming of PUFAs-associated metabolism during trastuzumab resistance formation of HER2-positive breast cancer
    Yin, Yongmei
    Duan, Ningjun
    Hua, Yijia
    Hu, Shuang
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Reprogramming of oncogenic signal pathways and metabolism during trastuzumab resistance formation of HER2 positive breast cancer
    Duan, Ningjun
    Hua, Yijia
    Hu, Shuang
    Yin, Yongmei
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Altered epigenetic modifications and genome architecture reshape lipid metabolism during secondary trastuzumab resistance formation of HER2-positive breast cancer
    Duan, Ningjun
    Hua, Yijia
    Yin, Yongmei
    CANCER RESEARCH, 2024, 84 (09)
  • [4] Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer
    Sonnenblick, Amir
    Salmon-Divon, Mali
    Salgado, Roberto
    Ponde, Noam
    Loibl, Sibylle
    Denkert, Carsten
    Joensuu, Heikki
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Azaria, Amos
    Loi, Sherene
    Michiels, Stefan
    Sotiriou, Christos
    CANCER RESEARCH, 2020, 80 (04)
  • [5] Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer
    Sonnenblick, Amir
    Salmon-Divon, Mali
    Salgado, Roberto
    Dvash, Efrat
    Ponde, Noam
    Zahavi, Tamar
    Salmon, Asher
    Loibl, Sibylle
    Denkert, Carsten
    Joensuu, Heikki
    Ameye, Lieveke
    Van den Eynden, Gert
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Azaria, Amos
    Loi, Sherene
    Michiels, Stefan
    Richard, Francois
    Sotiriou, Christos
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (01) : 266 - 276
  • [6] HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch
    Dubianski, R.
    Sarnowska, E.
    Leszczynski, M.
    Kubala, S.
    Olszewski, W.
    Rusetska, N.
    Jagiello-Gruszfeld, A. I.
    Konopinski, R.
    Sarnowski, T. J.
    Siedlecki, J. A.
    Nowecki, Z. I.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
    Hori, Ami
    Shimoda, Masafumi
    Naoi, Yasuto
    Kagara, Naofumi
    Tanei, Tomonori
    Miyake, Tomohiro
    Shimazu, Kenzo
    Kim, Seung Jin
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [8] Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
    Ami Hori
    Masafumi Shimoda
    Yasuto Naoi
    Naofumi Kagara
    Tomonori Tanei
    Tomohiro Miyake
    Kenzo Shimazu
    Seung Jin Kim
    Shinzaburo Noguchi
    Breast Cancer Research, 21
  • [9] PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer
    Xin Zhao
    Yang Li
    Hongyan Zhang
    Yihang Cai
    Xu Wang
    Yidu Liu
    Tingting Li
    Chendong Xu
    Yuee Teng
    Danni Li
    Feng Li
    Cell Death & Disease, 16 (1)
  • [10] Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer
    Ji-Won Kim
    Debora K. Kim
    Ahrum Min
    Kyung-Hun Lee
    Hyun-Jin Nam
    Jee Hyun Kim
    Jin-Soo Kim
    Tae-Yong Kim
    Seock-Ah Im
    In Ae Park
    Journal of Cancer Research and Clinical Oncology, 2016, 142 : 157 - 165
12345